HUTCHMED is a biopharmaceutical company that discovers, develops, and commercializes oncology and immunology medicines, with deep roots in China and a growing international presence. Its portfolio includes marketed cancer drugs and a pipeline of targeted therapies and combinations aimed at solid tumors and other indications. The business model combines in-house R&D with partnerships for global development and commercialization outside core markets.
| Year | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| 2022 | 426.4 | — | -360.8 | — |
| 2023 | 838 | 96.5% | 100.8 | — |
| 2024 | 630.2 | -24.8% | 37.7 | -62.6% |
| 2025 | 548.5 | -13% | 456.9 | 1,111% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Ethos Technologies Inc. (LIFE), Strive, Inc. (ASST), First Busey Corporation (BUSE), Beam Therapeutics Inc. (BEAM), OneSpaWorld Holdings Limited (OSW), H2O America (HTO)